Progenra Inc.
Malvern, PA
- UEI
- Z3JKMHXHFHJ6
- CAGE
- 45R38
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 271a Great Valley Pkwy, Malvern, PA 19355, USA
- Website
- progenra.com
- Founded
- 2005
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Progenra Inc.
Progenra Inc. is a biotechnology firm located in Malvern, Pennsylvania, registered as a for-profit Subchapter S Corporation since 2005. The company specializes in drug discovery and development, with a particular focus on innovative therapeutic approaches targeting the ubiquitin proteasome system (UPS). Their proprietary UbiProTM drug discovery platform enables the development of small molecule compounds that modulate protein interactions and cellular processes, with an emphasis on creating novel therapeutic interventions for various medical conditions.
Through its federal grant awards, Progenra has pursued advanced research in multiple critical medical domains, predominantly funded by prestigious National Institutes of Health (NIH) institutes. The company has received multiple Small Business Innovation Research (SBIR) grants targeting specific disease treatments, including tuberculosis (funded by the National Institute of Allergy and Infectious Diseases), pancreatitis (National Institute of Diabetes and Digestive and Kidney Diseases), rheumatoid arthritis (National Institute of Arthritis and Musculoskeletal and Skin Diseases), heart failure (National Heart, Lung, and Blood Institute), and diabetes (National Institute of Diabetes and Digestive and Kidney Diseases). Their research consistently involves developing innovative small molecule compounds that activate or degrade specific proteins to address underlying disease mechanisms, with a particular emphasis on ubiquitin pathway modulation. The grants demonstrate Progenra's sophisticated approach to drug discovery, focusing on targeted protein manipulation through mechanisms like parkin activation, IRAK4 degradation, and TXNIP reduction across various cellular and animal model studies.
Quick answers
What is Progenra Inc.'s UEI?
Progenra Inc.'s Unique Entity ID (UEI) in SAM.gov is Z3JKMHXHFHJ6.
What is Progenra Inc.'s CAGE code?
Progenra Inc.'s CAGE code is 45R38.
Where is Progenra Inc. located?
Progenra Inc.'s physical address in SAM.gov is 271a Great Valley Pkwy, Malvern, PA 19355, USA.
Is Progenra Inc. registered in SAM.gov?
Yes. Progenra Inc.'s SAM.gov registration is active through November 18, 2026.
What is Progenra Inc.'s most recent federal award?
Progenra Inc.'s most recent federal grant award is Ubiquitin pathway modulators as novel antituberculosis drugs - new approaches are needed to treat niaid priority… (R43AI191788), from National Institute of Allergy and Infectious Diseases, on May 16, 2025.
On GovTribe
See Progenra Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors